With respect to hormone receptor status, lobular, ductal/lobular, mucinous, tubular, and papillary carcinoma cases were 0.2–0.4-fold less likely to be diagnosed with ER−/PR− tumours, while comedo, medullary, and inflammatory cases were 1.7–11.6-fold more likely to be diagnosed with ER−/PR− tumours compared to ductal carcinoma cases. This evidence concerns the gene NR4A1 and neoplasm.